JP2009524697A5 - - Google Patents

Download PDF

Info

Publication number
JP2009524697A5
JP2009524697A5 JP2008552611A JP2008552611A JP2009524697A5 JP 2009524697 A5 JP2009524697 A5 JP 2009524697A5 JP 2008552611 A JP2008552611 A JP 2008552611A JP 2008552611 A JP2008552611 A JP 2008552611A JP 2009524697 A5 JP2009524697 A5 JP 2009524697A5
Authority
JP
Japan
Prior art keywords
fumaric acid
containing cores
acid
except
instead
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008552611A
Other languages
English (en)
Japanese (ja)
Other versions
JP5433236B2 (ja
JP2009524697A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/061217 external-priority patent/WO2007090082A2/en
Publication of JP2009524697A publication Critical patent/JP2009524697A/ja
Publication of JP2009524697A5 publication Critical patent/JP2009524697A5/ja
Application granted granted Critical
Publication of JP5433236B2 publication Critical patent/JP5433236B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2008552611A 2006-01-27 2007-01-29 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系 Expired - Fee Related JP5433236B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76275006P 2006-01-27 2006-01-27
US60/762,750 2006-01-27
PCT/US2007/061217 WO2007090082A2 (en) 2006-01-27 2007-01-29 Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013165542A Division JP5918179B2 (ja) 2006-01-27 2013-08-08 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系

Publications (3)

Publication Number Publication Date
JP2009524697A JP2009524697A (ja) 2009-07-02
JP2009524697A5 true JP2009524697A5 (enExample) 2010-03-25
JP5433236B2 JP5433236B2 (ja) 2014-03-05

Family

ID=38325269

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008552611A Expired - Fee Related JP5433236B2 (ja) 2006-01-27 2007-01-29 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系
JP2013165542A Expired - Fee Related JP5918179B2 (ja) 2006-01-27 2013-08-08 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系
JP2015188001A Withdrawn JP2016014048A (ja) 2006-01-27 2015-09-25 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013165542A Expired - Fee Related JP5918179B2 (ja) 2006-01-27 2013-08-08 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系
JP2015188001A Withdrawn JP2016014048A (ja) 2006-01-27 2015-09-25 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系

Country Status (14)

Country Link
US (1) US20070190145A1 (enExample)
EP (2) EP2363117B1 (enExample)
JP (3) JP5433236B2 (enExample)
KR (1) KR101413613B1 (enExample)
CN (2) CN103211779B (enExample)
AU (1) AU2007211091B8 (enExample)
BR (1) BRPI0707324A2 (enExample)
CA (1) CA2640460C (enExample)
ES (2) ES2531215T3 (enExample)
IL (1) IL193020A0 (enExample)
NZ (1) NZ570039A (enExample)
RU (1) RU2490012C2 (enExample)
WO (1) WO2007090082A2 (enExample)
ZA (1) ZA200806497B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2640382C (en) * 2006-01-27 2015-12-29 Eurand, Inc Drug delivery systems comprising weakly basic drugs and organic acids
ES2692437T3 (es) * 2007-08-13 2018-12-03 Abuse Deterrent Pharmaceutical Llc Fármacos resistentes al abuso, método de uso y método de preparación
CA2708152A1 (en) * 2007-12-10 2009-06-18 Eurand, Inc Orally disintegrating tablets comprising diphenhydramine
RU2524638C2 (ru) * 2007-12-21 2014-07-27 Апталис Фарматех Инк. Орально распадающиеся таблеточные композиции темазепама
NZ586870A (en) * 2007-12-28 2012-10-26 Impax Laboratories Inc Controlled release formulations of levodopa, carbidopa andd a caboxylic acid
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
EP2329823A4 (en) * 2008-09-03 2013-04-03 Takeda Pharmaceutical PROCESS FOR INCREASING THE ABSORPTION ABILITY OF A PREPARATION AND PREPARATION WITH INCREASED ABSORPTION ABILITY
EP2398470A4 (en) * 2009-02-23 2013-03-06 Aptalis Pharmatech Inc CONTROLLED RELEASE COMPOSITIONS COMPRISING A PROTON PUMP INHIBITOR
RU2011145278A (ru) * 2009-04-09 2013-05-20 Алкермес Фарма Айэленд Лимитед Композиции клозапина с контролируемым высвобождением
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
BR112012012999A2 (pt) 2009-11-30 2019-04-02 Aptalis Pharmatech Inc Composição farmacêutica, e composição de tablete de desintegração oral (odt) outablete de dispersão rápida (rdt)
BR112012013011A2 (pt) * 2009-11-30 2015-09-08 Aptalis Pharmatech Inc odt; composição de odt; método para a preparação de um tablete de odt multiparticulado, método para tratar ou prevenir náusea e vômito pós operatória ou náusea e vômito pós- alta por até 24 horas após a dosagem, método para tratar pu prevenir náusea por até 24 horas após a dosagem e método para tratar ou prevenir náusea e vômito associados a radioterapia em pacientes que recebem ou irradiação de corpo total, dose alta única ao abdômen, ou frações diárias ao abdômen por até 24 horas após a dosagem
KR101143997B1 (ko) * 2010-03-04 2012-05-09 한미사이언스 주식회사 유산균 제제 및 5-ｈｔ4 수용체 효능제를 함유하는 경구 투여용 복합 제제 및 이의 제조방법
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
MX365568B (es) 2010-12-02 2019-06-07 Adare Pharmaceuticals Inc Granulos de dispersion rapida, comprimidos de disolucion oral y metodos.
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
JP6506271B2 (ja) 2013-10-07 2019-04-24 インパックス ラボラトリーズ、 インコーポレイテッドＩｍｐａｘ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． レボドパ及び／又はレボドパのエステルの粘膜付着性制御放出配合物、並びにその使用
CN106061292B (zh) * 2013-12-16 2020-01-21 麻省理工学院 强化的微量营养素盐调配物
SG11201607511WA (en) * 2014-03-11 2016-10-28 Redhill Biopharma Ltd Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
CN106999436B (zh) * 2014-10-01 2021-07-02 奥克希托恩生物科学公司 含有分娩控制物质的口服崩解固体药物剂量单元
US10172913B2 (en) * 2014-10-01 2019-01-08 Oxytone Bioscience B.V. Orally disintegrating solid pharmaceutical dosage unit containing a partus control substance
CN104473895A (zh) * 2014-11-20 2015-04-01 美吉斯制药（厦门）有限公司 拉莫三嗪口腔崩解缓释片
US10406336B2 (en) 2016-08-03 2019-09-10 Neil S. Davey Adjustable rate drug delivery implantable device
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN108624005B (zh) * 2017-03-24 2021-10-29 华东理工大学 基于poc和介孔纳米微球的双因子缓释系统
KR20230011359A (ko) 2020-06-18 2023-01-20 엑스더블유파마 리미티드 수용성 활성 약제 성분의 제어 방출 과립화물
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
WO2022076466A1 (en) 2020-10-05 2022-04-14 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
KR20230124622A (ko) 2020-12-22 2023-08-25 암닐 파마슈티컬스 엘엘씨 레보도파 투여 요법
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
EP4588471A3 (en) 2021-03-19 2025-09-24 XWPharma Ltd. Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative
WO2022233885A2 (en) * 2021-05-03 2022-11-10 Cambridge Glycoscience Ltd Soluble and insoluble saccharide compositions and related methods
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3634584A (en) * 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
IE48715B1 (en) * 1978-12-22 1985-05-01 Elan Corp Plc New galencial forms for administration of medicaments by oral route,with programmed release and processes for preparing same
US4381546A (en) * 1979-03-02 1983-04-26 Paradyne Corporation System for the quantitative measurement of impairments in the communication channel of a quadrature amplitude modulation data communication system
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
EP0225085A1 (en) * 1985-11-13 1987-06-10 ELAN CORPORATION, Plc Controlled absorption pharmaceutical formulation
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
WO1992020326A1 (en) * 1991-05-20 1992-11-26 Marion Laboratories, Inc. Multi-layered controlled release formulation
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
JPH0710745A (ja) * 1993-06-22 1995-01-13 Tanabe Seiyaku Co Ltd 放出開始時間制御型腸デリバリー経口製剤
JPH08157392A (ja) * 1994-12-01 1996-06-18 Kanegafuchi Chem Ind Co Ltd 放出制御型製剤
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
ES2178876T5 (es) * 1998-03-06 2012-10-01 Aptalis Pharma S.R.L. Pastilla de desintegración rápida
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
DK1126826T6 (en) * 1998-11-02 2019-06-24 Alkermes Pharma Ireland Ltd Multiparticulate modified release of methylphenidate
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6936275B2 (en) * 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
IL150657A0 (en) * 2000-01-20 2003-02-12 Delsys Pharmaceutical Corp Multi-step drug dosage forms
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
AU2002230935A1 (en) * 2000-10-30 2002-05-15 Teva Pharmaceutical Industries Ltd. Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
US8765176B2 (en) * 2001-06-20 2014-07-01 Takeda Pharmaceutical Campany Limited Method of manufacturing tablet
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US20040019096A1 (en) * 2001-10-23 2004-01-29 Vlassios Andronis Novel formulations of carvedilol
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
MY139719A (en) * 2002-02-12 2009-10-30 Glaxo Group Ltd Oral dosage form for controlled drug release
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
WO2004096182A1 (en) * 2003-04-30 2004-11-11 Ranbaxy Laboratories Limited Extended release matrix tablets of carvedilol
DE10353186A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
WO2005077341A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Orally disintegrating pharmaceutical compositions of ondansetron
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
AU2005237360B2 (en) * 2004-04-30 2010-10-21 Astellas Pharma Inc. Time-limited release type granular pharmaceutical composition for oral administration and intraoral rapid disintegration tablet containing the composition
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ728442A (en) 2004-10-21 2018-05-25 Adare Pharmaceuticals Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
CA2635313C (en) * 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
RS50842B (sr) * 2006-10-24 2010-08-31 Helsinn Healthcare S.A. Meke kapsule koje sadrže palonosetron hlorovodonik koji ima poboljšanu stabilnost i bioraspoloživost
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids

Similar Documents

Publication Publication Date Title
JP2009524697A5 (enExample)
LTC3170818I2 (lt) Kietos 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties formos
JP2011508438A5 (enExample)
IL237820A (en) Using a History of 4- (1-Carboxy-Ethylcarbamoyl) -4- (5- [2,1] Ditheolan-3-Il-Pentanoylamino) - Butyric Acid for Drug Preparation
JP2012065100A5 (enExample)
EP2367808A4 (en) PROGESTATIVE 3- (6,6-ETHYLENE-17b-HYDROXY-3-OXO-17a-PREGNA-4-EN-17a-YL) PROPIONIC ACID g-LACTONE
JP2011506530A5 (enExample)
JP2012502876A5 (enExample)
JP2010195825A5 (enExample)
JP2011526809A5 (enExample)
JP2013507321A5 (enExample)
JP2010518805A5 (enExample)
JP2014047406A5 (enExample)
JP2012117142A5 (enExample)
JP2013507408A5 (enExample)
WO2010151095A8 (en) Novel acetylsalicylic acid salts
JP2013500200A5 (enExample)
JP2011525472A5 (enExample)
JP2009544651A5 (enExample)
JP2009504909A5 (enExample)
JP2007045756A5 (enExample)
JP2016502452A5 (enExample)
JP2013536814A5 (enExample)
JP2008517002A5 (enExample)
JP2013539979A5 (enExample)